For Canadians with type 2 diabetes, Retatrutide may eventually complement or reduce reliance on Metformin, but replacement depends on individual factors your healthcare provider must assess
Do not remain on this dose beyond four weeks without consulting your doctor
For the treatment of obesity, GLP-1RAs and GIP/ GLP-1RAs are indicated in patients with a body mass index (BMI) 30 kg m 2 , or 27 kg m 2 in the presence of at least one weight-related comorbidity, to support weight reduction [23]
it requires comprehensive support, expert medical oversight, and a customized approach to your unique health profile
These findings have catalyzed a paradigm shift in addiction neuroscience
One targets GLP-1, GIP and a third hormone, glucagon